The study of diagnosis and treatment of facial palsy

The study to develop novel diagnostic method and treatment in facial palsy caused by virus infection

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031190235

Enrollment

564

Registered

2020-03-02

Start date

2020-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial palsy caused by viral peripheral neuritis HSV-1, VZV, Facial palsy

Interventions

Randomized controlled trial of steroid dose A group. start dose of prednisolone is 60mg. Tapering off in 10 days. B group. start dose of prednisolone is 120mg. Tapering off in 10 days.

D016449

Randomized Controlled Trial

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Facial palsy patients 7 days or less after onset 2. Moderate or severe facial palsy patients(Yanagihara score is 18 and under) 3. Obtained written informed consent

Exclusion criteria

Exclusion criteria: Patients who are contraindications or relative contraindications to administration of test drug, prednisolone.

Design outcomes

Primary

Measure	Time frame
Recovery rate of facial palsy.	—

Secondary

Measure	Time frame
Improvement rate of facial palsy Incidence of adverse event Developing diagnostic method of causing virus Evaluation about quality of life relating facial palsy	—

Contacts

Public ContactKoichiro Wasano

Tokai University Hospital

wasano@tokai.ac.jp+81-463-93-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026